Key result
Early initiation of chemotherapy based on clinical diagnosis of pulmonary tumor thrombotic microangiopathy temporarily improved respiratory failure in a patient with lung adenocarcinoma.
Why the study?
Pulmonary tumor thrombotic microangiopathy is a rare, rapidly progressive fatal cancer complication with limited treatment options, diagnostic challenges, and poorly understood long-term management.
Case Report (n=1)
No
This case highlights that early clinical diagnosis and chemotherapy can improve outcomes in pulmonary tumor thrombotic microangiopathy.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare and fatal lung complication associated with cancer. Diagnosing PTTM is challenging due to its rapid progression and nonspecific clinical or imaging findings, which often result in postmortem identification. Treatment options are limited, and long-term management remains poorly understood. This report describes a 50-year-old patient with lung adenocarcinoma who was clinically diagnosed with PTTM and showed improvement with early chemotherapy initiation. Disease activity was controlled through multiple chemotherapy regimens, and recurrence was monitored using blood coagulation status and echocardiography. This case highlights the importance of early clinical diagnosis and ongoing monitoring of disease progression in PTTM.
No takes yet. Share an insight, caveat, or question.
Hamakawa et al. (2025) conducted a case report in Pulmonary tumor thrombotic microangiopathy (PTTM) caused by lung adenocarcinoma (n=1). Chemotherapy was evaluated. Early initiation of chemotherapy based on clinical diagnosis of pulmonary tumor thrombotic microangiopathy temporarily improved respiratory failure in a patient with lung adenocarcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: